Hypoxia Response Pathway as a Target for Novel Therapeutics

Johanna Myllyharju, Ph.D. and Peppi Karppinen, M.D., Ph.D.

Project leaders
Prof. Johanna Myllyharju, Ph.D.
Prof. Peppi Karppinen (née) Koivunen, M.D., Ph.D.

Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine

Mailing address
P.O. Box 5000, FIN-90014 University of Oulu, FINLAND

Street address
University of Oulu, Aapistie 7, FIN-90220 Oulu, Finland

e-mail: johanna.myllyharju (at) oulu.fi, tel. +358-(0)294 485740
e-mail: peppi.karppinen (at) oulu.fi, tel. +358-(0)294 485822

Focus area spearhead project web page:

About the project

The rescue response of cells to hypoxia is mediated by hypoxia-inducible factor (HIF), which activates genes required for increased oxygen delivery and reduced oxygen consumption. HIF accumulates in hypoxia but is rapidly degraded in normoxia by an oxygen sensing mechanism provided by HIF prolyl 4-hydroxylases (HIF-P4Hs). This central role of HIF-P4Hs makes them promising drug candidates as their inhibitors may offer novel therapeutics for diseases associated with hypoxia. Our objective is to investigate the potential of HIF-P4Hs and related enzymes as drug targets to treat several common diseases, such as ischemic conditions, metabolic dysfunction and atherosclerosis, inflammatory diseases, fibrosis and cancer. The project is part of the Finnish Centre of Excellence Programme funded by the Academy of Finland (Centre of Excellence Grant 2012 - 2017, 251314).

Project details

  1. Background and Significance
  2. Recent Progress
  3. Future Goals
  4. Publications 2017-
  5. Research Group Members
  6. National and International Activities

Last updated: 31.1.2019